The Bull Rankings scorecard — our quality-growth score is 59.7 / 100, built from three pillars scored 0–100: Quality 48, Growth 60, Value 86 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 8% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Takeda’s current price sits at $18.21 against a market cap of $58.2 b, a P/S of 1.9 and a PEG of 0.42. Our model gives it a 59.7/100 quality‑growth score, with Value 86 topping the chart and Quality 48 trailing. The upside comes from the Value pillar, the stock also trades at a modest 1.9× sales, below the sector median, and the analyst consensus of $22.78 implies a 25 % upside. The 0.42 PEG says the multiple is low against the earnings growth analysts expect. In short, the price is cheap on several measures, and the consensus target suggests analysts still see room for gains.
What the business actually is
Takeda is a specialty drugmaker that develops, manufactures, markets, and out‑licenses products across five therapeutic areas: gastroenterology, rare diseases, plasma‑derived therapies, oncology, and vaccines. Its flagship brands include Entyvio, Takhzyro, and Gattex/Revestive, alongside rare‑disease drugs such as Advate and Replagal and a large portfolio of plasma‑derived immunoglobulin therapies. The company’s revenue engine is driven by a mix of high‑margin specialty drugs and a growing rare‑disease pipeline that taps unmet needs.
Why it can (or can't) keep compounding
The durability of Takeda’s business hinges on its high‑margin specialty portfolio and the regulatory moat surrounding plasma‑derived therapies. Profit margins sit at a thin 2.4 %, and the company’s debt‑to‑equity of 0.73 keeps leverage in check. Free cash flow of $3.2 b indicates the firm can fund growth without external debt. The model’s Foreign reporter (JPY) flag notes that Takeda reports in yen, so currency swings can move the dollar figures we use. Competitors cannot replicate plasma‑derived manufacturing at scale without significant capital and regulatory hurdles, giving Takeda a defensible niche.
The valuation question
Our reverse‑DCF shows that the current price implies ~8 %/yr free‑cash‑flow growth (in year one, slowing to 3% a year by year ten). Revenue grew 7.5 % YoY in FY 2025, so the implied FCF growth is only modestly higher than top‑line growth. The low PEG of 0.42 points the same way: the price asks little of the business. The P/S of 1.9 is comfortably below the sector average, and the analyst target range of $21.74–$23.87 translates to a 20–30 % upside. Therefore, the price already assumes a realistic growth trajectory; it is not overly optimistic, nor is it deeply pessimistic.
The bear case
The weakest pillar in our model is Quality 48. A low quality score flags operational fragility or thin margins. Takeda’s profit margin of 2.4 % is thin for a drugmaker, held down partly by amortization from its Shire acquisition, even as it generates $3.2 b of free cash flow against a $58.2 b market cap. If key drugs lose patent protection faster than new launches replace them, the 8 % FCF growth implied by the price becomes harder to reach, and the 25 % upside could evaporate.
What would change our mind
- Margin lift: If Takeda raises its profit margin above 3.5 %, the valuation would shift from a modest upside to a compelling one.
- Revenue growth acceleration: Sustained revenue growth above 10 % YoY for two consecutive years would validate the 8 % FCF growth assumption and justify the analyst target.
- Quality pillar improvement: A jump in the quality score from 48 to 60—for example, through a successful pipeline launch or cost‑control initiative—would remove the primary risk and tilt the balance toward a bullish stance.